IFM 99-02 Thalidomide in Myeloma

Inclusion Criteria: * de novo myeloma * according to Durie and Salmon classification stage II, III and stage I with a lytic bone lesion * patients from 18 to 65 years old * beta2microglobulin \< 3 mg/l or del13 absent * signed informed consent * eligible for transplantation Exclusion Criteria: * peripheral neurological toxicities * uncontrolled or severe cardiovascular disease * other malignancy except basocellular carcinoma or FIGO stage I carcinoma of the cervix * patient who received biphosphonate during the last 60 days * renal failure definited as creatinine \> 150 µmol/l * patient with obvious vascular cerebral medical history * liver dysfunction definited as bilirubin \> 35 µmol/l or ASAT, ALAT, PAL \> 4N * respiratory dysfunction * HIV + * Patient who refused to use an acceptable barrier method for contraception